CA
NZ
UK
AU
IND
US
…
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alphatec Holdings (ATEC) is a medical device company that designs, develops and sells spinal fusion implants, biologics and surgical technologies to hospitals and spine surgeons with a focus on minimally invasive approaches. Long-term growth may be supported by aging demographics, wider adoption of minimally invasive spine procedures and expansion of its commercial footprint and product portfolio. The company may appeal to investors seeking exposure to a focused spine franchise with recurring implant sales and potential margin improvement from scale.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -143.40M | -162.07M | -186.91M | -152.01M | -144.16M |
| Net income | -143.36M | -162.12M | -186.64M | -152.15M | -144.33M |
| Selling general administrative | 498.53M | 450.20M | 351.88M | 300.01M | 229.27M |
| Gross profit | 531.89M | 424.26M | 310.20M | 233.06M | 157.76M |
| Reconciled depreciation | 82.56M | 83.32M | 54.90M | 43.93M | 30.17M |
| Ebit | -122.26M | -137.19M | -170.27M | -121.10M | -108.87M |
| Ebitda | -39.70M | -53.87M | -110.59M | -110.52M | -105.09M |
| Depreciation and amortization | 82.56M | 83.32M | 59.68M | 10.59M | 3.79M |
| Operating income | -82.13M | -136.17M | -173.40M | -121.10M | -108.87M |
| Other operating expenses | 846.28M | 747.73M | 655.66M | 471.97M | 352.08M |
| Interest expense | 21.14M | 24.88M | 16.64M | 5.50M | 7.11M |
| Tax provision | -0.04M | 0.05M | 0.18M | 0.14M | 0.16M |
| Net interest income | -45.92M | -24.88M | -13.55M | -5.50M | -7.11M |
| Non recurring | - | - | - | - | 8.06M |
| Income tax expense | -0.04M | 0.05M | -0.28M | 0.14M | 0.16M |
| Total revenue | 764.15M | 611.56M | 482.26M | 350.87M | 243.21M |
| Total operating expenses | 614.02M | 560.43M | 483.60M | 354.16M | 266.63M |
| Cost of revenue | 232.27M | 187.30M | 172.06M | 117.81M | 85.45M |
| Total other income expense net | -61.27M | -25.90M | -13.52M | -30.91M | -35.29M |
| Net income from continuing ops | -143.36M | -162.12M | -173.20M | -152.15M | -144.33M |
| Net income applicable to common shares | - | - | - | -152.15M | -144.33M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 791.21M | 775.71M | 805.21M | 513.38M | 572.05M |
| Intangible assets | 93.45M | 93.52M | 102.45M | 82.78M | 85.27M |
| Other current assets | 23.32M | 20.31M | 20.67M | 9.36M | 10.31M |
| Total liab | 755.18M | 766.28M | 703.49M | 550.09M | 492.63M |
| Total stockholder equity | 36.03M | 9.43M | 101.72M | -36.71M | 79.42M |
| Deferred long term liab | - | - | - | 1.30M | - |
| Other current liab | 97.02M | 78.96M | 87.71M | 72.38M | 55.55M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -1424.44M | -1281.09M | -1118.96M | -934.47M | -782.33M |
| Other liab | - | - | - | 11.54M | 367.93M |
| Good will | 75.21M | 70.98M | 73.00M | 39.77M | 39.69M |
| Other assets | - | - | 0.00M | 4.87M | 3.25M |
| Cash | 160.81M | 138.84M | 220.97M | 84.70M | 187.25M |
| Total current liabilities | 219.18M | 153.03M | 157.57M | 138.87M | 101.09M |
| Current deferred revenue | 10.44M | 10.47M | 13.91M | 11.96M | 15.26M |
| Net debt | 459.14M | 471.10M | 320.71M | 311.17M | -182.69M |
| Short term debt | 70.82M | 8.11M | 6.97M | 19.79M | 4.55M |
| Short long term debt | 64.53M | 1.66M | 1.81M | 14.95M | 0.34M |
| Short long term debt total | 619.95M | 609.94M | 541.68M | 395.86M | 4.55M |
| Other stockholder equity | 1441.28M | 1280.58M | 1205.39M | 884.84M | 844.13M |
| Property plant equipment | - | - | - | 130.31M | 112.68M |
| Total current assets | 450.88M | 417.40M | 451.09M | 255.63M | 331.16M |
| Net tangible assets | - | - | - | -159.27M | -45.54M |
| Net receivables | 97.30M | 82.99M | 72.61M | 60.06M | 41.89M |
| Long term debt | 501.41M | 574.52M | 511.04M | 349.51M | 326.49M |
| Inventory | 169.44M | 175.26M | 136.84M | 101.52M | 91.70M |
| Accounts payable | 40.89M | 52.98M | 48.98M | 34.74M | 25.74M |
| Accumulated other comprehensive income | -4.43M | -13.68M | -8.32M | -10.69M | -5.99M |
| Common stock total equity | - | - | - | - | 0.01M |
| Retained earnings total equity | - | - | - | - | -782.33M |
| Treasury stock | - | - | - | - | -25.10M |
| Non currrent assets other | 5.12M | 2.72M | 2.42M | 4.87M | 3.25M |
| Non current assets total | 340.33M | 358.31M | 354.12M | 257.74M | 240.90M |
| Capital lease obligations | 30.15M | 33.76M | 28.84M | 31.40M | 28.59M |
| Long term debt total | - | - | - | - | 326.49M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -3.00M | -93.14M | -128.60M | -58.28M | -3.00M |
| Change to liabilities | - | - | - | 7.52M | 12.59M |
| Total cashflows from investing activities | -53.41M | -93.14M | - | -58.28M | -157.76M |
| Net borrowings | 74.81M | 58.80M | - | 35.00M | 306.22M |
| Total cash from financing activities | 30.02M | 56.21M | 356.92M | 31.23M | 311.97M |
| Change to operating activities | - | - | - | 8.93M | 13.25M |
| Net income | -143.36M | -162.12M | -186.64M | -152.15M | -144.33M |
| Change in cash | 21.97M | -82.13M | 136.27M | -102.55M | 79.48M |
| Begin period cash flow | 138.84M | 220.97M | 84.70M | 187.25M | 107.77M |
| End period cash flow | 160.81M | 138.84M | 220.97M | 84.70M | 187.25M |
| Total cash from operating activities | 45.23M | -44.65M | -78.48M | -75.14M | -73.43M |
| Issuance of capital stock | 0.00M | 0.00M | 67.43M | 57.51M | 131.83M |
| Depreciation | 105.08M | 83.32M | 59.68M | 43.93M | 30.17M |
| Other cashflows from investing activities | -10.96M | -93.14M | - | - | -86.22M |
| Dividends paid | - | - | 1.06M | 3.04M | 316.25M |
| Change to inventory | 13.54M | -54.66M | -45.56M | -20.70M | -27.75M |
| Change to account receivables | -21.88M | -14.59M | -12.79M | -18.83M | -10.14M |
| Sale purchase of stock | - | - | -1.06M | -3.04M | -30.96M |
| Other cashflows from financing activities | -44.80M | -2.03M | -4.86M | -0.73M | 572.35M |
| Change to netincome | - | - | - | 54.13M | 59.88M |
| Capital expenditures | 42.45M | 93.14M | 86.97M | 58.28M | 68.54M |
| Change receivables | - | - | - | - | -10.14M |
| Cash flows other operating | - | - | - | - | 7.69M |
| Exchange rate changes | - | - | - | - | -1.29M |
| Cash and cash equivalents changes | - | - | - | - | 79.48M |
| Change in working capital | -20.13M | -67.27M | -54.18M | -23.09M | -23.88M |
| Stock based compensation | 73.72M | 73.28M | 81.24M | 40.56M | 36.45M |
| Other non cash items | 29.92M | 28.15M | 21.41M | 15.61M | 4.59M |
| Free cash flow | 2.78M | -137.79M | -165.46M | -133.42M | -141.98M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATEC Alphatec Holdings Inc |
-4.33 38.08% |
7.04 | - | 56.50 | 2.08 | 140.82 | 2.86 | -18.89 |
| ABT Abbott Laboratories |
1.63 1.56% |
106.20 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.57 0.59% |
96.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.89 6.38% |
291.86 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
1950 Camino Vida Roble, Carlsbad, CA, United States, 92008
760 431 9286
913
| Name | Title | Year Born |
|---|---|---|
| Mr. Patrick S. Miles | Exec. Chairman, CEO & Pres | 1966 |
| Mr. J. Todd Koning | Exec. VP & CFO | 1973 |
| Mr. Craig E. Hunsaker | Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel | 1964 |
| Mr. Brian R. Snider | Exec. VP of Marketing | 1978 |
| Mr. David P. Sponsel | Exec. VP of Sales | 1979 |
| Mr. Jonathan Allen | Exec. VP of Commercial Operations | 1960 |
| Mr. Scott Lish | Sr. VP of R&D | 1982 |
| Dr. Luiz Pimenta | Chief Medical Officer | NA |
| Ms. Kelli Mari Howell | Exec. VP of Clinical Strategies | 1974 |
| Mr. Eric Dasso | Exec. VP of Adjunctive Technologies | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...